Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. Hassan, Q., Roche, B., Buffet, C., Bessede, T., Samuel, D., Charpentier, B., & Durrbach, A. Transpl Int, 25(9):941–7, September, 2012. ![Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.
@article{hassan_liver-kidney_2012,
title = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},
volume = {25},
issn = {1432-2277 (ELECTRONIC) 0934-0874 (LINKING)},
shorttitle = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22882335},
abstract = {Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.},
number = {9},
journal = {Transpl Int},
author = {Hassan, Q. and Roche, B. and Buffet, C. and Bessede, T. and Samuel, D. and Charpentier, B. and Durrbach, A.},
month = sep,
year = {2012},
keywords = {Acute, Adult, Aged, Agents/therapeutic, Biopsy, C/*immunology/*virology, Failure/*therapy/virology, Female, Graft, Hepatitis, Humans, Immunosuppressive, Insufficiency/*therapy/virology, Interferon-alpha/*therapeutic, Kidney, Liver, Liver/pathology, Male, Middle, Outcome, Recurrence, Rejection, Renal, Retrospective, Ribavirin/*therapeutic, Steroids/therapeutic, Studies, Transaminases/metabolism, Transplantation/*methods, Treatment, disease, use},
pages = {941--7},
}
Downloads: 0
{"_id":"dy9i4CmuHR4ib5kTN","bibbaseid":"hassan-roche-buffet-bessede-samuel-charpentier-durrbach-liverkidneyrecipientswithchronicviralhepatitisctreatedwithinterferonalpha-2012","author_short":["Hassan, Q.","Roche, B.","Buffet, C.","Bessede, T.","Samuel, D.","Charpentier, B.","Durrbach, A."],"bibdata":{"bibtype":"article","type":"article","title":"Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha","volume":"25","issn":"1432-2277 (ELECTRONIC) 0934-0874 (LINKING)","shorttitle":"Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha","url":"http://www.ncbi.nlm.nih.gov/pubmed/22882335","abstract":"Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.","number":"9","journal":"Transpl Int","author":[{"propositions":[],"lastnames":["Hassan"],"firstnames":["Q."],"suffixes":[]},{"propositions":[],"lastnames":["Roche"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Buffet"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Bessede"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Samuel"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Charpentier"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Durrbach"],"firstnames":["A."],"suffixes":[]}],"month":"September","year":"2012","keywords":"Acute, Adult, Aged, Agents/therapeutic, Biopsy, C/*immunology/*virology, Failure/*therapy/virology, Female, Graft, Hepatitis, Humans, Immunosuppressive, Insufficiency/*therapy/virology, Interferon-alpha/*therapeutic, Kidney, Liver, Liver/pathology, Male, Middle, Outcome, Recurrence, Rejection, Renal, Retrospective, Ribavirin/*therapeutic, Steroids/therapeutic, Studies, Transaminases/metabolism, Transplantation/*methods, Treatment, disease, use","pages":"941–7","bibtex":"@article{hassan_liver-kidney_2012,\n\ttitle = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},\n\tvolume = {25},\n\tissn = {1432-2277 (ELECTRONIC) 0934-0874 (LINKING)},\n\tshorttitle = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/22882335},\n\tabstract = {Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.},\n\tnumber = {9},\n\tjournal = {Transpl Int},\n\tauthor = {Hassan, Q. and Roche, B. and Buffet, C. and Bessede, T. and Samuel, D. and Charpentier, B. and Durrbach, A.},\n\tmonth = sep,\n\tyear = {2012},\n\tkeywords = {Acute, Adult, Aged, Agents/therapeutic, Biopsy, C/*immunology/*virology, Failure/*therapy/virology, Female, Graft, Hepatitis, Humans, Immunosuppressive, Insufficiency/*therapy/virology, Interferon-alpha/*therapeutic, Kidney, Liver, Liver/pathology, Male, Middle, Outcome, Recurrence, Rejection, Renal, Retrospective, Ribavirin/*therapeutic, Steroids/therapeutic, Studies, Transaminases/metabolism, Transplantation/*methods, Treatment, disease, use},\n\tpages = {941--7},\n}\n\n\n\n","author_short":["Hassan, Q.","Roche, B.","Buffet, C.","Bessede, T.","Samuel, D.","Charpentier, B.","Durrbach, A."],"key":"hassan_liver-kidney_2012","id":"hassan_liver-kidney_2012","bibbaseid":"hassan-roche-buffet-bessede-samuel-charpentier-durrbach-liverkidneyrecipientswithchronicviralhepatitisctreatedwithinterferonalpha-2012","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/22882335"},"keyword":["Acute","Adult","Aged","Agents/therapeutic","Biopsy","C/*immunology/*virology","Failure/*therapy/virology","Female","Graft","Hepatitis","Humans","Immunosuppressive","Insufficiency/*therapy/virology","Interferon-alpha/*therapeutic","Kidney","Liver","Liver/pathology","Male","Middle","Outcome","Recurrence","Rejection","Renal","Retrospective","Ribavirin/*therapeutic","Steroids/therapeutic","Studies","Transaminases/metabolism","Transplantation/*methods","Treatment","disease","use"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":["acute","adult","aged","agents/therapeutic","biopsy","c/*immunology/*virology","failure/*therapy/virology","female","graft","hepatitis","humans","immunosuppressive","insufficiency/*therapy/virology","interferon-alpha/*therapeutic","kidney","liver","liver/pathology","male","middle","outcome","recurrence","rejection","renal","retrospective","ribavirin/*therapeutic","steroids/therapeutic","studies","transaminases/metabolism","transplantation/*methods","treatment","disease","use"],"search_terms":["liver","kidney","recipients","chronic","viral","hepatitis","treated","interferon","alpha","hassan","roche","buffet","bessede","samuel","charpentier","durrbach"],"title":"Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha","year":2012}